ArticleInflammation2025
WFS1 Gene Mutation (c.2389G > A) Induces Immune Disorders by Promoting DC Maturation through Inhibition of TMEM176A.
Article in Inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Mutations in the WFS1 gene, encoding wolframin (WFS1), are known to cause endoplasmic reticulum (ER) stress and lead to Wolfram Syndrome (WS). However, the role of WFS1 in immune inflammation remains unexplored. In this study, we identified that the WFS1 gene mutation (c.2389G > A) not only results in WS associated symptoms but also induces the elevated levels of pro-inflammatory cytokines (i.e. TNF-α, IL-1β, and IL-6), and promotes the maturation of dendritic cell (DC) in WFS1 mutated mice. Silencing the WFS1 gene in DCs also promoted DC maturation and inflammation while also increasing DC apoptosis. Further investigation revealed that WFS1 regulates the expression of X-box binding protein 1 (XBP1), which negatively modulates the expression of TMEM176A, thereby affecting the maturation, inflammatory response, and function of DCs. Additionally, WFS1 influences DC apoptosis under ER stress (ERS) through the ATF4/CHOP pathway. Notably, the WFS1 mutation (c.2389G > A) induces immune cell apoptosis in experimental autoimmune uveitis (EAU). This study is the first to report the immune regulatory mechanism of WFS1 in DCs. The identification of a systemic chronic inflammatory state associated with WFS1 deficiency offers new insights that may facilitate the development of innovative, personalized therapeutic approaches for WS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.